What is HC Wainwright’s Estimate for REGENXBIO Q1 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at HC Wainwright decreased their Q1 2026 EPS estimates for REGENXBIO in a research note issued on Monday, March 9th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of ($1.23) for the quarter, down from their prior estimate of ($1.21). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2026 earnings at ($1.23) EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at ($1.24) EPS and FY2026 earnings at ($3.38) EPS.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). The business had revenue of $30.34 million for the quarter, compared to analyst estimates of $45.48 million. REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%.

RGNX has been the topic of a number of other reports. Leerink Partners lifted their target price on REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. UBS Group restated an “overweight” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Tuesday, February 10th. Wall Street Zen lowered shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. The Goldman Sachs Group dropped their target price on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Finally, Morgan Stanley reduced their target price on shares of REGENXBIO from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $27.50.

REGENXBIO Price Performance

NASDAQ RGNX opened at $9.38 on Wednesday. The firm has a market cap of $484.10 million, a price-to-earnings ratio of -2.49 and a beta of 1.08. REGENXBIO has a 1 year low of $5.03 and a 1 year high of $16.19. The company has a fifty day moving average price of $11.21 and a 200-day moving average price of $11.45.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue purchased a new stake in REGENXBIO during the third quarter valued at about $25,000. Aquatic Capital Management LLC bought a new stake in REGENXBIO in the third quarter valued at approximately $37,000. Jones Financial Companies Lllp boosted its position in REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,270 shares during the period. Steward Partners Investment Advisory LLC grew its stake in shares of REGENXBIO by 754.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of REGENXBIO during the second quarter valued at approximately $85,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Key Headlines Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Interim AFFINITY data show continued functional improvement and a clean safety profile at the pivotal dose—cardiac MRI stability at 1 year, functional measures exceeded external controls (including in patients aged 8+), and liver‑safety markers were supportive; company says pivotal topline data expected Q2 2026. REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX‑202
• Positive Sentiment: Independent reporting (Reuters) corroborates company claims: early‑to‑mid stage trial showed improved muscle function and a favorable safety profile, which supports the therapeutic and regulatory narrative for RGX‑202. Regenxbio’s Duchenne gene therapy shows improved muscle function in trial
• Neutral Sentiment: Market reaction was mixed: some outlets note progress but frame headlines as “mixed signals” because strong clinical readouts coexist with other headwinds. This explains why positive data did not produce an unambiguous rally. Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals
• Neutral Sentiment: HC Wainwright updated model assumptions: reduced near‑term EPS estimates but kept a Buy rating and $30 target while adjusting later‑year estimates higher — a sign analysts still see upside but expect short‑term cost/earnings pressure. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: RBC Capital reaffirmed its Buy rating, which supports longer‑term sentiment among some institutional analysts despite near‑term volatility. RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX)
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for securities class actions covering a broad period through Jan 27, 2026; active litigation risk and potential settlements or disclosures are ongoing negative catalysts. RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP
• Negative Sentiment: Additional plaintiff firms (Levi & Korsinsky, Pomerantz, Rosen, Schall, Gross, Rosen) have issued notices—heightening litigation visibility and potential legal costs or management distraction. Levi & Korsinsky investor notice

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.